BRPI0515646A - proteìna de domìnio catalìtico de sialidase, molécula de ácido nucléico, proteìna de fusão, vetor de expressão, formulação farmacêutica, método de tratamento ou prevenção de infecção viral pelo vìrus de influenza, parainfluenza, ou syncytial respiratório, método de tratamento ou prevenção de infecção por um patógeno bacteriano, método de tratamento ou prevenção de alergia ou inflamação, método de intensificação da aplicação de gene por um vetor viral recombinante, método de tratamento ou prevenção de infecção por influenza - Google Patents
proteìna de domìnio catalìtico de sialidase, molécula de ácido nucléico, proteìna de fusão, vetor de expressão, formulação farmacêutica, método de tratamento ou prevenção de infecção viral pelo vìrus de influenza, parainfluenza, ou syncytial respiratório, método de tratamento ou prevenção de infecção por um patógeno bacteriano, método de tratamento ou prevenção de alergia ou inflamação, método de intensificação da aplicação de gene por um vetor viral recombinante, método de tratamento ou prevenção de infecção por influenzaInfo
- Publication number
- BRPI0515646A BRPI0515646A BRPI0515646-7A BRPI0515646A BRPI0515646A BR PI0515646 A BRPI0515646 A BR PI0515646A BR PI0515646 A BRPI0515646 A BR PI0515646A BR PI0515646 A BRPI0515646 A BR PI0515646A
- Authority
- BR
- Brazil
- Prior art keywords
- prevention
- treatment
- treating
- preventing
- infection
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 11
- 230000002265 prevention Effects 0.000 title abstract 8
- 108090000623 proteins and genes Proteins 0.000 title abstract 5
- 102000005348 Neuraminidase Human genes 0.000 title abstract 4
- 108010006232 Neuraminidase Proteins 0.000 title abstract 4
- 102000004169 proteins and genes Human genes 0.000 title abstract 3
- 206010020751 Hypersensitivity Diseases 0.000 title abstract 2
- 206010061218 Inflammation Diseases 0.000 title abstract 2
- 208000026935 allergic disease Diseases 0.000 title abstract 2
- 230000007815 allergy Effects 0.000 title abstract 2
- 230000003197 catalytic effect Effects 0.000 title abstract 2
- 230000002708 enhancing effect Effects 0.000 title abstract 2
- 239000013604 expression vector Substances 0.000 title abstract 2
- 108020001507 fusion proteins Proteins 0.000 title abstract 2
- 230000004054 inflammatory process Effects 0.000 title abstract 2
- 108020004707 nucleic acids Proteins 0.000 title abstract 2
- 102000039446 nucleic acids Human genes 0.000 title abstract 2
- 150000007523 nucleic acids Chemical class 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 230000003612 virological effect Effects 0.000 title abstract 2
- 208000002606 Paramyxoviridae Infections Diseases 0.000 title 1
- 244000052616 bacterial pathogen Species 0.000 title 1
- 102000037865 fusion proteins Human genes 0.000 title 1
- 206010022000 influenza Diseases 0.000 title 1
- 230000000241 respiratory effect Effects 0.000 title 1
- 241000712461 unidentified influenza virus Species 0.000 title 1
- 239000013603 viral vector Substances 0.000 title 1
- 208000015181 infectious disease Diseases 0.000 abstract 5
- 150000001875 compounds Chemical class 0.000 abstract 4
- 239000000203 mixture Substances 0.000 abstract 3
- 244000052769 pathogen Species 0.000 abstract 3
- 230000001717 pathogenic effect Effects 0.000 abstract 3
- 241000700605 Viruses Species 0.000 abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- 230000000172 allergic effect Effects 0.000 abstract 1
- 208000010668 atopic eczema Diseases 0.000 abstract 1
- 230000001580 bacterial effect Effects 0.000 abstract 1
- 108020001778 catalytic domains Proteins 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000001415 gene therapy Methods 0.000 abstract 1
- 230000028709 inflammatory response Effects 0.000 abstract 1
- 230000026683 transduction Effects 0.000 abstract 1
- 238000010361 transduction Methods 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
- C12N15/75—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Bacillus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01018—Exo-alpha-sialidase (3.2.1.18), i.e. trans-sialidase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Plant Pathology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Otolaryngology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
PROTEìNA DE DOMìNIO CATALìTICO DE SIALIDASE, MOLéCULA DE áCIDO NUCLéICO, PROTEìNA DE FUSãO, VETOR DE EXPRESSãO, FORMULAçãO FARMACêUTICA, MéTODO DE TRATAMENTO OU PREVENçãO DE INFECçãO VIRAL PELO VìRUS DE INFLUENZA, PARAINFLUENZA, OU SYNCYTIAL RESPIRATóRIO, MéTODO DE TRATAMENTO OU PREVENçãO DE INFECçãO POR UM PATóGENO BACTERIANO, MéTODO DE TRATAMENTO OU PREVENçãO DE ALERGIA OU INFLAMAçãO, MéTODO DE INTENSIFICAçãO DA APLICAçãO DE GENE POR UM VETOR VIRAL RECOMBINANTE, MéTODO DE TRATAMENTO OU PREVENçãO DE INFECçãO POR INFLUENZA A presente invenção apresenta novas composições e métodos para a prevenção e o tratamento de infecção por patógenos. Particularmente, a presente invenção apresenta compostos que têm um domínio de ancoragem que ancora o composto à superfície de uma célula alvo, e um domínio terapêutico de que pode agir extracelularmente para impedir a infecção de uma célula alvo por um patógeno, tal como um vírus. A presente invenção também compreende também composições terapêuticas que têm a atividade da sialidase, incluindo compostos à base de proteínas que têm domínios catalíticos de sialidase. Os compostos da invenção podem ser utilizados no tratamento ou na prevenção da infecção por patógenos, e para o tratamento e a redução de respostas alérgicas e inflamatórias. A invenção também apresenta composições e métodos para incrementar a transdução de células alvo por vírus recombinantes. Tais composições e métodos podem ser utilizados na terapia de genes.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/939,262 US7807174B2 (en) | 2002-11-22 | 2004-09-10 | Class of therapeutic protein based molecules |
| US10/939,262 | 2004-09-10 | ||
| PCT/US2005/025831 WO2006031291A2 (en) | 2004-09-10 | 2005-07-21 | A novel class of therapeutic protein based molecules |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| BRPI0515646A true BRPI0515646A (pt) | 2008-07-15 |
| BRPI0515646A8 BRPI0515646A8 (pt) | 2017-04-04 |
| BRPI0515646B1 BRPI0515646B1 (pt) | 2020-10-13 |
| BRPI0515646B8 BRPI0515646B8 (pt) | 2021-05-25 |
Family
ID=36060467
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0515646A BRPI0515646B8 (pt) | 2004-09-10 | 2005-07-21 | proteína de fusão e formulação farmacêutica |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US7807174B2 (pt) |
| EP (4) | EP3018204B1 (pt) |
| JP (2) | JP4764881B2 (pt) |
| KR (1) | KR20070064619A (pt) |
| CN (2) | CN101426906B (pt) |
| AU (1) | AU2005285461B2 (pt) |
| BR (1) | BRPI0515646B8 (pt) |
| CA (2) | CA2823429C (pt) |
| DK (3) | DK1786902T3 (pt) |
| ES (3) | ES2626845T3 (pt) |
| IL (3) | IL181779A (pt) |
| PT (3) | PT3241898T (pt) |
| RU (1) | RU2468080C2 (pt) |
| TR (1) | TR201905393T4 (pt) |
| WO (1) | WO2006031291A2 (pt) |
| ZA (1) | ZA200702915B (pt) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100210528A1 (en) * | 1999-03-05 | 2010-08-19 | Leland Shapiro | Compositions, methods and uses for inhibition and/or treatment of influenza infection |
| US7807174B2 (en) * | 2002-11-22 | 2010-10-05 | Nexbio, Inc. | Class of therapeutic protein based molecules |
| CN1729013B (zh) * | 2002-11-22 | 2012-10-03 | 耐百生物制药有限公司 | 广谱抗病毒化合物、药物制剂及其用途 |
| US8512710B2 (en) | 2002-11-22 | 2013-08-20 | Ansun Biopharma, Inc. | Class of therapeutic protein based molecules |
| CN101002512B (zh) * | 2004-11-10 | 2013-12-04 | 日立化成株式会社 | 附有粘着辅助剂的金属箔及使用其的印刷配线板 |
| CN101553581A (zh) * | 2005-10-25 | 2009-10-07 | Mnd诊断有限公司 | 用于检测流感病毒的组合物以及使用该组合物的试剂盒和方法 |
| AU2015215955B2 (en) * | 2006-01-24 | 2016-12-01 | Ansun Biopharma, Inc. | Technology for preparation of macromolecular microspheres |
| AU2013237761B8 (en) * | 2006-01-24 | 2015-06-04 | Ansun Biopharma, Inc. | Technology for preparation of macromolecular microspheres |
| EP1981483A1 (en) * | 2006-01-24 | 2008-10-22 | Nexbio, Inc. | Technology for preparation of macromolecular microspheres |
| US8273381B1 (en) * | 2006-04-14 | 2012-09-25 | Auburn University | Compositions for and methods of controlling olfactory responses to odorants |
| WO2008076938A1 (en) * | 2006-12-14 | 2008-06-26 | University Of Iowa Research Foundation | Method of making cyclic polypeptides with inteins |
| JP5436225B2 (ja) * | 2007-02-20 | 2014-03-05 | ディーエスエム アイピー アセッツ ビー．ブイ． | 新規シアリダーゼ |
| US8124632B2 (en) * | 2007-08-03 | 2012-02-28 | Romark Laboratories, L.C. | Alkylsulfonyl-substituted thiazolide compounds |
| EP3078377A3 (en) * | 2009-05-12 | 2017-04-05 | Romark Laboratories, L.C. | Nitazoxanide and tizoxanide as anti-viral agents |
| MX341877B (es) | 2009-06-26 | 2016-09-06 | Romark Laboratories L C * | Compuestos y métodos para tratar influenza. |
| EP2459714A1 (en) * | 2009-07-31 | 2012-06-06 | Danisco US Inc. | Proteases with modified pre-pro regions |
| JP2013510169A (ja) * | 2009-11-06 | 2013-03-21 | ネクスバイオ，インク． | 呼吸器管の治療及び予防のための方法、化合物、及び組成物 |
| CA2864746A1 (en) | 2012-02-17 | 2013-08-22 | Ansun Biopharma, Inc. | Methods, compounds and compositions for treatment of influenza and parainfluenza patients |
| US20140154308A1 (en) * | 2012-06-28 | 2014-06-05 | Ansun Biopharma, Inc. | Microparticle Formulations for Delivery to the Upper and Central Respiratory Tract and Methods of Manufacture |
| JP2015527310A (ja) | 2012-06-28 | 2015-09-17 | アンサン バイオファーマ, インコーポレイテッドAnsun Biopharma, Inc. | 下気道および中枢気道への送達用微粒子製剤ならびに製造方法 |
| KR102047235B1 (ko) | 2012-12-24 | 2019-11-22 | 바이엘 헬스케어 엘엘씨 | 단작용성 인자 vii 폴리펩티드 |
| JP6471385B2 (ja) | 2013-03-15 | 2019-02-20 | グラディエーター・バイオサイエンシーズ・インコーポレイテッド | 標的化剤としてのＧｌａドメイン |
| US10351828B2 (en) * | 2013-03-15 | 2019-07-16 | Ansun Biopharma, Inc. | Method of protein purification from E. coli |
| WO2014197485A1 (en) * | 2013-06-03 | 2014-12-11 | Ansun Biopharma, Inc. | Anti-viral therapeutic for infection of the eye |
| US20160120961A1 (en) * | 2013-06-10 | 2016-05-05 | Ansun Biopharma, Inc. | Treatment of merkel cell polyomavirus infection |
| US10300116B2 (en) | 2013-06-10 | 2019-05-28 | Ansun Biopharma, Inc. | Treatment for BK polyomavirus infection |
| US20170119859A1 (en) | 2014-05-30 | 2017-05-04 | Ansun Biopharma, Inc. | Treatment of middle east respiratory syndrome coronavirus |
| WO2016044656A1 (en) | 2014-09-17 | 2016-03-24 | Ansun Biopharma, Inc. | Treatment of infection by human enterovirus d68 |
| US9616114B1 (en) | 2014-09-18 | 2017-04-11 | David Gordon Bermudes | Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity |
| WO2016115616A1 (en) * | 2015-01-21 | 2016-07-28 | Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Health | Inhibition of cellular proteases as treatment for influenza |
| US10676723B2 (en) | 2015-05-11 | 2020-06-09 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| SG10202100652VA (en) | 2015-07-21 | 2021-03-30 | Univ Jefferson | Gene therapies for neurodegenerative disorders targeting ganglioside biosynthetic pathways |
| DK3458085T5 (da) | 2016-05-20 | 2024-09-09 | Octapharma Ag | Glykosyleret vwf-fusionsproteiner med forbedret farmakokinetik |
| ES2947312T3 (es) | 2016-07-01 | 2023-08-04 | Univ Leland Stanford Junior | Conjugados para la edición dirigida de la superficie celular |
| US11129906B1 (en) | 2016-12-07 | 2021-09-28 | David Gordon Bermudes | Chimeric protein toxins for expression by therapeutic bacteria |
| US11180535B1 (en) | 2016-12-07 | 2021-11-23 | David Gordon Bermudes | Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria |
| PL3630968T3 (pl) | 2017-05-26 | 2024-10-07 | Genovis Ab | Enzymy do analizy glikanów |
| PE20201462A1 (es) | 2017-09-05 | 2020-12-17 | Gladiator Biosciences Inc | Metodo de direccionamiento de exosomas |
| JP7462560B2 (ja) | 2018-01-03 | 2024-04-05 | パレオン ファーマシューティカルズ インコーポレイテッド | 組換えヒトシアリダーゼ、シアリダーゼ融合タンパク質およびそれらの使用方法 |
| GB201800274D0 (en) * | 2018-01-08 | 2018-02-21 | Enzymatica Ab | Novel treatments |
| GB201803197D0 (en) | 2018-02-27 | 2018-04-11 | Pneumagen Ltd | Viral treatment |
| US20220370527A1 (en) * | 2018-07-20 | 2022-11-24 | Ansun Biopharma, Inc. | Delivery of sialidase to cancer cells, immune cells and the tumor microenvironment |
| CN109991649B (zh) * | 2019-03-26 | 2021-04-06 | 华中科技大学 | 一种制备无机闪烁体膜的方法 |
| JP7343890B2 (ja) * | 2019-04-26 | 2023-09-13 | 国立大学法人東海国立大学機構 | シアリダーゼ活性を有する酵素剤及びその利用 |
| CN110038122A (zh) * | 2019-05-23 | 2019-07-23 | 武汉真福医药股份有限公司 | 枯草杆菌纤溶酶在治疗支气管炎药物中的应用 |
| CA3145200A1 (en) | 2019-07-03 | 2021-01-07 | Aillis Inc. | Pharmaceutical composition for treating influenza virus infections |
| CN111450236B (zh) * | 2020-02-25 | 2023-04-07 | 西北大学 | 一种用于阻断冠状病毒感染的制剂 |
| WO2021217053A1 (en) * | 2020-04-24 | 2021-10-28 | Rezolute, Inc. | Plasma kallikrein inhibitors for the treatment of ards and related conditions |
| WO2021252129A1 (en) * | 2020-06-10 | 2021-12-16 | The Penn State Research Foundation | Process and system to lessen human coronavirus transmission and spread |
| WO2022147481A1 (en) | 2020-12-30 | 2022-07-07 | Ansun Biopharma Inc. | Combination therapy of an oncolytic virus delivering a foreign antigen and an engineered immune cell expressing a chimeric receptor targeting the foreign antigen |
| JP2024524875A (ja) * | 2021-06-09 | 2024-07-09 | マイクロビアル マシーンズ， インコーポレイテッド | 疾患細胞を検出するための操作された微生物 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3439089A (en) | 1968-03-27 | 1969-04-15 | Merck & Co Inc | Medicated hard candy |
| ATE135403T1 (de) * | 1987-03-10 | 1996-03-15 | New England Biolabs Inc | Herstellung und reinigung eines proteins, das mit einem bindungsprotein fusioniert ist |
| US5643758A (en) | 1987-03-10 | 1997-07-01 | New England Biolabs, Inc. | Production and purification of a protein fused to a binding protein |
| RU2054180C1 (ru) | 1991-08-21 | 1996-02-10 | Жирнов Олег Петрович (н/п) | Способ лечения вирусных респираторных инфекций |
| US5376633A (en) | 1992-09-30 | 1994-12-27 | Lezdey; John | Method for deactivating viruses in blood component containers |
| US5985859A (en) * | 1994-04-14 | 1999-11-16 | The University Of Alabama | Methods of inhibiting bacterial sialidase |
| BR9506262A (pt) * | 1994-06-14 | 1997-08-12 | Gist Brocades Bv | Xilanase sequência de dna isolada e purificada vetor células hospedeira microbiana microorganismo isolado processos para a preparação de uma xilanase para a degradação de xilano para deslignificar pasta de madeira e produto obtido após o tratamento da pasta de madeira |
| US5952375A (en) * | 1995-02-27 | 1999-09-14 | Gilead Sciences, Inc. | Compounds and methods for synthesis and therapy |
| GB9513683D0 (en) * | 1995-07-05 | 1995-09-06 | Ciba Geigy Ag | Products |
| AU5546898A (en) | 1997-01-14 | 1998-08-07 | Hopital Sainte-Justine | Human lysosomal sialidase and therapeutic uses thereof |
| US6251392B1 (en) | 1997-10-20 | 2001-06-26 | Epicyte Pharmaceuticals, Inc. | Epithelial cell targeting agent |
| US6737511B1 (en) | 1999-08-16 | 2004-05-18 | The United States Of America As Represented By The Department Of Health And Human Services | Receptor-mediated uptake of an extracellular BCL-xL fusion protein inhibits apoptosis |
| US20020025320A1 (en) | 1999-08-20 | 2002-02-28 | Prosper Boyaka | Sialidases as mucosal adjuvants |
| CN1405562A (zh) * | 2002-10-24 | 2003-03-26 | 肖洪武 | 一种唾液酸酶测定试剂 |
| US7807174B2 (en) | 2002-11-22 | 2010-10-05 | Nexbio, Inc. | Class of therapeutic protein based molecules |
| CN1729013B (zh) | 2002-11-22 | 2012-10-03 | 耐百生物制药有限公司 | 广谱抗病毒化合物、药物制剂及其用途 |
| DE10258400A1 (de) * | 2002-12-13 | 2004-06-24 | N.V. Nutricia | Trans-Sialidasen aus Trypanosoma congolense |
| EP1981483A1 (en) | 2006-01-24 | 2008-10-22 | Nexbio, Inc. | Technology for preparation of macromolecular microspheres |
-
2004
- 2004-09-10 US US10/939,262 patent/US7807174B2/en not_active Expired - Lifetime
-
2005
- 2005-07-21 PT PT17164276T patent/PT3241898T/pt unknown
- 2005-07-21 JP JP2007531167A patent/JP4764881B2/ja not_active Expired - Fee Related
- 2005-07-21 AU AU2005285461A patent/AU2005285461B2/en not_active Expired
- 2005-07-21 EP EP15180371.5A patent/EP3018204B1/en not_active Expired - Lifetime
- 2005-07-21 CN CN2005800372268A patent/CN101426906B/zh not_active Expired - Lifetime
- 2005-07-21 CN CN201310239638.6A patent/CN104017787B/zh not_active Expired - Lifetime
- 2005-07-21 EP EP19153015.3A patent/EP3530734A1/en not_active Withdrawn
- 2005-07-21 DK DK05790917.8T patent/DK1786902T3/en active
- 2005-07-21 RU RU2007112502/10A patent/RU2468080C2/ru active
- 2005-07-21 DK DK15180371.5T patent/DK3018204T3/en active
- 2005-07-21 PT PT151803715T patent/PT3018204T/pt unknown
- 2005-07-21 TR TR2019/05393T patent/TR201905393T4/tr unknown
- 2005-07-21 DK DK17164276.2T patent/DK3241898T3/en active
- 2005-07-21 PT PT57909178T patent/PT1786902E/pt unknown
- 2005-07-21 ES ES15180371.5T patent/ES2626845T3/es not_active Expired - Lifetime
- 2005-07-21 KR KR1020077008112A patent/KR20070064619A/ko not_active Withdrawn
- 2005-07-21 ES ES05790917.8T patent/ES2554787T3/es not_active Expired - Lifetime
- 2005-07-21 EP EP17164276.2A patent/EP3241898B1/en not_active Expired - Lifetime
- 2005-07-21 ES ES17164276T patent/ES2721172T3/es not_active Expired - Lifetime
- 2005-07-21 WO PCT/US2005/025831 patent/WO2006031291A2/en not_active Ceased
- 2005-07-21 BR BRPI0515646A patent/BRPI0515646B8/pt active IP Right Grant
- 2005-07-21 CA CA2823429A patent/CA2823429C/en not_active Expired - Lifetime
- 2005-07-21 CA CA2578050A patent/CA2578050C/en not_active Expired - Lifetime
- 2005-07-21 EP EP05790917.8A patent/EP1786902B1/en not_active Expired - Lifetime
-
2007
- 2007-03-07 IL IL181779A patent/IL181779A/en active IP Right Grant
- 2007-04-10 ZA ZA200702915A patent/ZA200702915B/xx unknown
-
2008
- 2008-10-22 US US12/256,230 patent/US7645448B2/en not_active Expired - Lifetime
-
2010
- 2010-07-05 JP JP2010153231A patent/JP5307082B2/ja not_active Expired - Fee Related
- 2010-09-02 IL IL207957A patent/IL207957A/en active IP Right Grant
-
2015
- 2015-09-06 IL IL241227A patent/IL241227B/en active IP Right Grant
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0515646A8 (pt) | Proteína de fusão e formulação farmacêutica | |
| Cattel et al. | Ozone therapy in COVID-19: A narrative review | |
| BR112022022456A2 (pt) | Proteínas de ligação de repetição de anquirina e seus usos | |
| Edwards et al. | The potential of anti‐infectives and immunomodulators as therapies for asthma and asthma exacerbations | |
| NO20071048L (no) | Amidoforbindelser og deres anvendelse som farmasoytika | |
| BRPI0517463A (pt) | inibidores da protease do vìrus da hepatite c, composições e tratamentos usando os mesmos | |
| BR112023002951A2 (pt) | Compostos de fosfolipídio e usos destes | |
| BR112022026321A2 (pt) | Análogos de 1'-ciano nucleosídeo e usos dos mesmos | |
| BRPI0517286A (pt) | modulação de rnai de rsv, piv e outras viroses respiratórias e empregos desta | |
| BRPI0411906A (pt) | compostos, processo para a sua preparação, composições farmacêuticas que compreendem os mesmos, método para tratar ou prevenir uma enfermidade mediada pela ativação da enzima de sintase de glicogênio, e utilização dos compostos | |
| BRPI0710671B8 (pt) | uso de um vetor de bacteriofágo viral adenoassociado (aavp) terapêutico para a fabricação de um medicamento para o tratamento e profilaxia de uma doença hiperproliferativa | |
| NO20085243L (no) | Farmasoytisk sammensetning til behandling av virusinfeksjoner og/eller tumorsykdommer gjennom inhibering av proteinfolding og Proteinnedbryting | |
| NO20070372L (no) | Amidoforbindelser og anvendelse derav som farmasoytiske preparater | |
| BRPI1012749A8 (pt) | molécula de ligação, variante funcional da molécula de ligação, imunoconjugado, composição farmacêutica, uso da molécula de ligação, molécula de ácido nucléico. vetor, hospedeiro, e , método para produzir uma molécula de ligação. | |
| EA200870216A1 (ru) | Амидо соединения и их применение в качестве лекарственных средств | |
| NO20064584L (no) | Tetrahydropyridoindolderivater | |
| BR112014011896A2 (pt) | agentes de rnai, composições e métodos de uso destes para o tratamento de doenças associadas à transtirretina (ttr) | |
| NO20071240L (no) | Terapeutiske anvendelser av RTP801 inhibitorer | |
| BRPI0410563B8 (pt) | compostos de pirazol-quinazolina, seus processos de preparação e composições farmacêuticas | |
| EA200900154A1 (ru) | Фосфинатные соединения (варианты), фармацевтическая композиция на их основе, способ лечения вирусного гепатита с с ее помощью, терапевтическое средство на их основе и названные соединения для изготовления лекарства от вирусного гепатита с | |
| BRPI0517481A (pt) | método para tratar, controlar ou evitar uma doença ou distúrbio parasìtico protozoário, e, composição farmacêutica | |
| BRPI0507041A (pt) | composto derivados de sulfonamida para o tratamento de doenças seus usos, processo para a preparação dos compostos e combinação de compostos | |
| BR112022022942A2 (pt) | Réplicon de rna que codifica uma proteína spike de coronavírus estabilizada | |
| BRPI0607927A2 (pt) | derivados de pirazol-pirimidina | |
| BR112014006207A2 (pt) | n-[4- (1h-pirazolo[3,4-b]pirazin-6-il)-fenil]-sulfonamidas, processo para sua preparação, composição que o compreende e seu uso como produtos farmacêuticos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B15K | Others concerning applications: alteration of classification |
Free format text: AS CLASSIFICACOES ANTERIORES ERAM: C12N 9/36 , C12N 1/21 , C07H 21/04 , C12N 15/75 Ipc: C12N 9/36 (2006.01), C12N 1/21 (2006.01), C07H 21/ |
|
| B25A | Requested transfer of rights approved |
Owner name: NEXBIO, INC. (US) |
|
| B25D | Requested change of name of applicant approved |
Owner name: ANSUN BIOPHARMA, INC. (US) |
|
| B25G | Requested change of headquarter approved |
Owner name: ANSUN BIOPHARMA, INC. (US) |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 13/10/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 21/07/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |